CY2016040I1 - Επιλογες θεραπειας για τη νοσο του fabry - Google Patents

Επιλογες θεραπειας για τη νοσο του fabry

Info

Publication number: CY2016040I1
Authority: CY; Cyprus
Prior art keywords: fabry; disease; treatment options; options; treatment
Prior art date: 2006-05-16

Application number

CY2016040C

Other languages

English (en)

Other versions

CY2016040I2 (el

Original Assignee

Amicus Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-16

Filing date

2016-11-15

Publication date

2017-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016040(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-11-15 Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.

2017-06-28 Publication of CY2016040I2 publication Critical patent/CY2016040I2/el

2017-06-28 Publication of CY2016040I1 publication Critical patent/CY2016040I1/el

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Ecology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Diabetes (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CY2016040C 2006-05-16 2016-11-15 Επιλογες θεραπειας για τη νοσο του fabry CY2016040I1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US80108906P	2006-05-16	2006-05-16
US85363106P	2006-10-23	2006-10-23
EP07797506.8A EP2024745B1 (en)	2006-05-16	2007-05-16	Assays for diagnosing and evaluating treatment options for fabry disease

Publications (2)

Publication Number	Publication Date
CY2016040I2 CY2016040I2 (el)	2017-06-28
CY2016040I1 true CY2016040I1 (el)	2017-06-28

Family

ID=38723987

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20141100377T CY1115180T1 (el)	2006-05-16	2014-05-27	Επιλογες θεραπειας για τη νοσο του fabry
CY20161100448T CY1117656T1 (el)	2006-05-16	2016-05-24	Επιλογες θεραπειας για τη νοσο του fabry
CY2016040C CY2016040I1 (el)	2006-05-16	2016-11-15	Επιλογες θεραπειας για τη νοσο του fabry

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20141100377T CY1115180T1 (el)	2006-05-16	2014-05-27	Επιλογες θεραπειας για τη νοσο του fabry
CY20161100448T CY1117656T1 (el)	2006-05-16	2016-05-24	Επιλογες θεραπειας για τη νοσο του fabry

Country Status (18)

Country	Link
US (9)	US7851143B2 (el)
EP (5)	EP2024745B1 (el)
JP (6)	JP2009537149A (el)
AU (1)	AU2007253900A1 (el)
CA (1)	CA2652553C (el)
CY (3)	CY1115180T1 (el)
DK (2)	DK2533050T6 (el)
ES (3)	ES2573498T3 (el)
HK (3)	HK1178975A1 (el)
HU (2)	HUE027569T2 (el)
LT (1)	LTC2787345I2 (el)
LU (1)	LU93312I2 (el)
MX (2)	MX351004B (el)
NL (1)	NL300843I2 (el)
PL (2)	PL2533050T6 (el)
PT (1)	PT2533050E (el)
SI (2)	SI2533050T1 (el)
WO (1)	WO2007137072A2 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2024745B1 (en)	2006-05-16	2015-07-08	Amicus Therapeutics, Inc.	Assays for diagnosing and evaluating treatment options for fabry disease
AU2008245578A1 (en) *	2007-04-26	2008-11-06	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en)	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
DK2946785T3 (en) *	2008-02-12	2019-02-18	Amicus Therapeutics Inc	PROCEDURE FOR PREVENTING RESPONSE TO DISEASES OF PHARMACOLOGICAL CHAPERONE TREATMENT
EP2260107A4 (en) *	2008-03-12	2011-03-23	Amicus Therapeutics Inc	TESTS FOR THE DIAGNOSIS AND ASSESSMENT OF TREATMENT OPTIONS FOR MORBUS POMPE
JP5739898B2 (ja) *	2009-11-17	2015-06-24	ベイラーリサーチインスティテュートＢａｙｌｏｒＲｅｓｅａｒｃｈＩｎｓｔｉｔｕｔｅ	心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３）
CA2791994A1 (en) *	2010-03-05	2011-09-09	Baylor Research Institute	Involvement of androgen/androgen receptor pathway in fabry disease
CA2829947C (en) *	2011-03-11	2019-01-15	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of fabry disease
HUE044867T2 (hu)	2011-05-12	2019-11-28	Proteostasis Therapeutics Inc	Proteosztázis szabályzók
US20150258081A1 (en) *	2011-12-22	2015-09-17	Centogene Ip Gmbh	Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
AU2013202368B2 (en)	2012-01-25	2016-06-16	Proteostasis Therapeutics, Inc.	Proteasome activity modulating compounds
WO2014127038A1 (en) *	2013-02-12	2014-08-21	Baylor Research Institute	Methods and compositions related to calcium homeostasis and fabry disease
JP6546923B2 (ja) *	2013-12-23	2019-07-17	ビーシーエヌペプタイズエセ．ア．ＢｃｎＰｅｐｔｉｄｅｓＳ．Ａ．	リソソーム蓄積障害または糖原病の処置における使用のためのエキソサイトーシス活性化化合物としてのビカルタミド類似体または（ｓ）−ビカルタミド
US9675627B2 (en) *	2014-04-14	2017-06-13	Amicus Therapeutics, Inc.	Dosing regimens for treating and/or preventing cerebral amyloidoses
US9957494B2 (en)	2014-07-25	2018-05-01	Shire Human Genetic Therapies, Inc.	Crystal structure of human four-phosphate adaptor protein 2 glycolipid transfer protein like domain
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
TW202408513A (zh) *	2016-07-19	2024-03-01	美商阿米庫斯醫療股份有限公司	治療ert初治的和已經歷ert的患者中之法布瑞氏症
US12020820B1 (en)	2017-03-03	2024-06-25	Cerner Innovation, Inc.	Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en)	2017-03-06	2022-05-17	Cerner Innovation, Inc.	Predicting glycogen storage diseases (Pompe disease) and decision support
EP3630114B1 (en) *	2017-05-30	2023-11-01	Amicus Therapeutics, Inc.	Migalastat for treating fabry patients having renal impairment
KR102631805B1 (ko)	2017-05-30	2024-01-31	아미쿠스 세라퓨틱스, 인코포레이티드	신장 손상을 갖는 파브리 환자를 치료하는 방법
US11923048B1 (en)	2017-10-03	2024-03-05	Cerner Innovation, Inc.	Determining mucopolysaccharidoses and decision support tool
ES2969263T3 (es) *	2018-02-06	2024-05-17	Amicus Therapeutics Inc	Tratamiento de pacientes con enfermedad de Fabry clásica con migalastat
AU2019217868A1 (en)	2018-02-06	2020-10-01	Amicus Therapeutics, Inc.	Use of migalastat for treating fabry disease in pregnant patients
WO2020006269A1 (en)	2018-06-27	2020-01-02	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
BR122023023216A2 (pt)	2018-06-27	2024-02-20	Proteostasis Therapeutics, Inc.	Compostos, composição farmacêutica e uso de uma quantidade eficaz de um composto
US20220184185A1 (en)	2018-07-25	2022-06-16	Modernatx, Inc.	Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
KR20220044560A (ko)	2019-08-07	2022-04-08	아미쿠스 세라퓨틱스, 인코포레이티드	Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11191827B1 (en)	2020-12-09	2021-12-07	Tevogen Bio Inc.	COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en)	2020-12-16	2023-04-11	Amicus Therapeutics, Inc.	Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990011353A1 (en) *	1989-03-24	1990-10-04	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
CA2086413A1 (en)	1990-06-29	1991-12-30	Yohji Ezure	Piperidine derivatives
US6270954B1 (en)	1996-04-10	2001-08-07	The Regents Of The University Of California	Correction of genetic defects using chemical chaperones
CA2250780A1 (en)	1996-04-10	1997-10-16	The Regents Of The University Of California	Correction of genetic defects using chemical chaperones
US6274597B1 (en) *	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en)	2001-10-09	2010-11-30	Oregon Health & Science University	Method for pharmacoperones correction of GnRHR mutant protein misfolding
CA2514642C (en)	2003-01-31	2015-03-17	Mount Sinai School Of Medicine Of New York University	Combination therapy for treating protein deficiency disorders
US7446098B2 (en) *	2003-02-18	2008-11-04	Mount Sinai School Of Medicine Of New York University	Combination therapy for treating protein deficiencies
WO2004103368A1 (en) *	2003-05-22	2004-12-02	The Hospital For Sick Children	Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
FR2861991B1 (fr)	2003-11-07	2008-01-18	Centre Nat Rech Scient	Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
CN1901907A (zh)	2003-11-12	2007-01-24	阿米库斯治疗学公司	用于治疗戈谢病的葡糖并咪唑和多羟基环己烯基胺衍生物
ES2705335T3 (es)	2005-05-17	2019-03-22	Amicus Therapeutics Inc	Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
JP5107350B2 (ja)	2005-06-08	2012-12-26	アミカスセラピューティックスインコーポレイテッド	イミノおよびアミノ糖の精製
KR20080033242A (ko)	2005-06-08	2008-04-16	아미쿠스 세라퓨틱스, 인코포레이티드	리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는ｃｎｓ 질환의 치료 방법
US20100004156A1 (en)	2005-07-27	2010-01-07	Shalesh Kaushal	Small Compounds That Correct Protein Misfolding and Uses Thereof
US7790364B2 (en)	2006-01-27	2010-09-07	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for high throughput screening of pharmacological chaperones
EP2024745B1 (en) *	2006-05-16	2015-07-08	Amicus Therapeutics, Inc.	Assays for diagnosing and evaluating treatment options for fabry disease
ATE500226T1 (de)	2006-09-22	2011-03-15	Krka Tovarna Zdravil D D Novo Mesto	Aripiprazolhemifumarat und verfahren zu dessen herstellung
EP2142197A4 (en)	2007-03-30	2010-11-10	Amicus Therapeutics Inc	PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS
AU2008245578A1 (en)	2007-04-26	2008-11-06	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en)	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
DK2946785T3 (en)	2008-02-12	2019-02-18	Amicus Therapeutics Inc	PROCEDURE FOR PREVENTING RESPONSE TO DISEASES OF PHARMACOLOGICAL CHAPERONE TREATMENT
US8321148B2 (en)	2008-10-24	2012-11-27	Amicus Therapeutics, Inc.	Multiple compartment dosing model
US20110070643A1 (en)	2009-05-26	2011-03-24	Do Hung V	Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
US9206457B2 (en)	2009-05-26	2015-12-08	Amicus Therapeutics, Inc.	Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
JP5739898B2 (ja)	2009-11-17	2015-06-24	ベイラーリサーチインスティテュートＢａｙｌｏｒＲｅｓｅａｒｃｈＩｎｓｔｉｔｕｔｅ	心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３）
CA2829947C (en)	2011-03-11	2019-01-15	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of fabry disease
US10155027B2 (en)	2012-07-17	2018-12-18	Amicus Therapeutics, Inc.	Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
EP2874648A4 (en)	2012-07-17	2015-12-30	Amicus Therapeutics Inc	CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN
JP7098529B2 (ja)	2016-03-22	2022-07-11	アミカスセラピューティックスインコーポレイテッド	Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法
TW202408513A (zh)	2016-07-19	2024-03-01	美商阿米庫斯醫療股份有限公司	治療ert初治的和已經歷ert的患者中之法布瑞氏症
EP3568152A1 (en)	2017-01-10	2019-11-20	Amicus Therapeutics, Inc.	Recombinant alpha-galactosidase a for treatment of fabry disease
KR102631805B1 (ko)	2017-05-30	2024-01-31	아미쿠스 세라퓨틱스, 인코포레이티드	신장 손상을 갖는 파브리 환자를 치료하는 방법
SG11202000423XA (en)	2017-07-19	2020-02-27	Amicus Therapeutics Inc	Treatment of fabry disease in ert-naïve and ert-experienced patients
TWI845479B (zh)	2017-08-28	2024-06-21	美商阿米庫斯醫療股份有限公司	增強及/或穩定Fabry氏症患者之心臟功能之方法
AU2019217868A1 (en)	2018-02-06	2020-10-01	Amicus Therapeutics, Inc.	Use of migalastat for treating fabry disease in pregnant patients
ES2969263T3 (es)	2018-02-06	2024-05-17	Amicus Therapeutics Inc	Tratamiento de pacientes con enfermedad de Fabry clásica con migalastat
FI3840753T3 (fi)	2018-08-20	2024-10-30	Amicus Therapeutics Inc	Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
WO2020252129A1 (en)	2019-06-11	2020-12-17	Amicus Therapeutics, Inc.	Methods of treating fabry disease in patients having renal impairment
KR20220044560A (ko)	2019-08-07	2022-04-08	아미쿠스 세라퓨틱스, 인코포레이티드	Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

2007
- 2007-05-16 EP EP07797506.8A patent/EP2024745B1/en active Active
- 2007-05-16 EP EP15173515.6A patent/EP2955520B1/en active Active
- 2007-05-16 AU AU2007253900A patent/AU2007253900A1/en not_active Abandoned
- 2007-05-16 SI SI200731457T patent/SI2533050T1/sl unknown
- 2007-05-16 HU HUE14168748A patent/HUE027569T2/en unknown
- 2007-05-16 ES ES14168748.3T patent/ES2573498T3/es active Active
- 2007-05-16 CA CA2652553A patent/CA2652553C/en active Active
- 2007-05-16 PT PT121684518T patent/PT2533050E/pt unknown
- 2007-05-16 ES ES15173515T patent/ES2709445T3/es active Active
- 2007-05-16 ES ES12168451.8T patent/ES2464527T7/es active Active
- 2007-05-16 PL PL12168451T patent/PL2533050T6/pl unknown
- 2007-05-16 DK DK12168451.8T patent/DK2533050T6/da active
- 2007-05-16 MX MX2013006681A patent/MX351004B/es unknown
- 2007-05-16 JP JP2009511222A patent/JP2009537149A/ja active Pending
- 2007-05-16 DK DK14168748.3T patent/DK2787345T3/en active
- 2007-05-16 EP EP18197135.9A patent/EP3457135B1/en active Active
- 2007-05-16 EP EP12168451.8A patent/EP2533050B3/en active Active
- 2007-05-16 MX MX2008014679A patent/MX2008014679A/es active IP Right Grant
- 2007-05-16 SI SI200731776A patent/SI2787345T1/sl unknown
- 2007-05-16 WO PCT/US2007/069046 patent/WO2007137072A2/en active Application Filing
- 2007-05-16 US US11/749,512 patent/US7851143B2/en active Active
- 2007-05-16 PL PL14168748T patent/PL2787345T3/pl unknown
- 2007-05-16 EP EP14168748.3A patent/EP2787345B8/en active Active
2009
- 2009-08-14 HK HK13106776.2A patent/HK1178975A1/xx unknown
- 2009-08-14 HK HK09107461.6A patent/HK1129458A1/xx unknown
2010
- 2010-12-13 US US12/966,904 patent/US20110104727A1/en not_active Abandoned
2012
- 2012-04-12 US US13/445,338 patent/US9000011B2/en active Active
- 2012-12-27 JP JP2012285265A patent/JP6026268B2/ja active Active
2014
- 2014-05-27 CY CY20141100377T patent/CY1115180T1/el unknown
2015
- 2015-03-09 US US14/641,707 patent/US9480682B2/en active Active
- 2015-07-31 JP JP2015151795A patent/JP2016006088A/ja not_active Withdrawn
2016
- 2016-05-24 CY CY20161100448T patent/CY1117656T1/el unknown
- 2016-06-15 HK HK16106878.6A patent/HK1218955A1/zh unknown
- 2016-10-31 US US15/338,923 patent/US9987263B2/en active Active
- 2016-11-11 NL NL300843C patent/NL300843I2/nl unknown
- 2016-11-15 CY CY2016040C patent/CY2016040I1/el unknown
- 2016-11-16 HU HUS1600048C patent/HUS1600048I1/hu unknown
- 2016-11-16 LU LU93312C patent/LU93312I2/fr unknown
- 2016-11-16 LT LTPA2016033C patent/LTC2787345I2/lt unknown
2018
- 2018-04-10 JP JP2018075570A patent/JP6800176B2/ja active Active
- 2018-05-08 US US15/974,217 patent/US10383864B2/en active Active
- 2018-05-08 US US15/974,222 patent/US10406143B2/en active Active - Reinstated
2019
- 2019-09-09 US US16/564,694 patent/US11241422B2/en active Active
2020
- 2020-07-27 JP JP2020126185A patent/JP7175297B2/ja active Active
2022
- 2022-02-07 US US17/665,969 patent/US20220160690A1/en active Pending
- 2022-11-08 JP JP2022178697A patent/JP2023027053A/ja active Pending

Also Published As

Publication number	Publication date
JP2020196717A (ja)	2020-12-10
MX2008014679A (es)	2009-04-14
ES2573498T3 (es)	2016-06-08
LU93312I2 (fr)	2017-01-26
JP2009537149A (ja)	2009-10-29
PL2787345T3 (pl)	2016-08-31
CY1117656T1 (el)	2017-05-17
HUS1600048I1 (hu)	2017-01-30
ES2464527T3 (es)	2014-06-03
ES2709445T3 (es)	2019-04-16
JP7175297B2 (ja)	2022-11-18
PT2533050E (pt)	2014-05-26
CY2016040I2 (el)	2017-06-28
EP2533050B1 (en)	2014-03-12
US7851143B2 (en)	2010-12-14
EP2533050A1 (en)	2012-12-12
DK2787345T3 (en)	2016-05-30
US11241422B2 (en)	2022-02-08
US20190388409A1 (en)	2019-12-26
WO2007137072A2 (en)	2007-11-29
HK1218955A1 (zh)	2017-03-17
JP2018138564A (ja)	2018-09-06
JP2023027053A (ja)	2023-03-01
CA2652553A1 (en)	2007-11-29
HK1178975A1 (en)	2013-09-19
NL300843I2 (el)	2016-12-21
LTPA2016033I1 (lt)	2016-12-12
SI2533050T1 (sl)	2014-07-31
HK1129458A1 (en)	2009-11-27
US20180250279A1 (en)	2018-09-06
ES2464527T7 (es)	2015-09-14
DK2533050T6 (da)	2015-09-21
US20150238474A1 (en)	2015-08-27
US9987263B2 (en)	2018-06-05
US20120220632A1 (en)	2012-08-30
JP2013100307A (ja)	2013-05-23
EP2955520B1 (en)	2018-10-31
US20170042868A1 (en)	2017-02-16
WO2007137072A3 (en)	2008-10-16
EP3457135A1 (en)	2019-03-20
EP2787345B8 (en)	2016-04-13
LTC2787345I2 (lt)	2017-10-10
AU2007253900A1 (en)	2007-11-29
EP2533050B3 (en)	2015-06-24
US10383864B2 (en)	2019-08-20
US9480682B2 (en)	2016-11-01
EP2955520A1 (en)	2015-12-16
SI2787345T1 (sl)	2016-08-31
US20080056994A1 (en)	2008-03-06
EP2787345B1 (en)	2016-02-24
US9000011B2 (en)	2015-04-07
US10406143B2 (en)	2019-09-10
US20220160690A1 (en)	2022-05-26
US20110104727A1 (en)	2011-05-05
EP2024745A4 (en)	2010-03-17
JP6800176B2 (ja)	2020-12-16
HUE027569T2 (en)	2016-10-28
EP2787345A1 (en)	2014-10-08
DK2533050T3 (da)	2014-06-02
JP6026268B2 (ja)	2016-11-16
CA2652553C (en)	2020-08-18
ES2464527T9 (es)	2015-07-24
US20180325881A1 (en)	2018-11-15
MX351004B (es)	2017-09-26
EP3457135B1 (en)	2024-12-04
PL2533050T6 (pl)	2016-05-31
EP2024745A2 (en)	2009-02-18
CY1115180T1 (el)	2016-12-14
EP2024745B1 (en)	2015-07-08
PL2533050T3 (pl)	2014-08-29
JP2016006088A (ja)	2016-01-14

Publication	Publication Date	Title
CY2016040I2 (el)	2017-06-28	Επιλογες θεραπειας για τη νοσο του fabry
BRPI0810646A2 (pt)	2014-11-04	" compostos farmacêuticos ".
EP1868459A4 (en)	2010-01-27	FUNCTIONAL SHOE
DE602005026825D1 (de)	2011-04-21	Endoskop
DE602005027052D1 (de)	2011-05-05	Endoskopbehandlungssystem
EP1908389A4 (en)	2011-03-02	MEDICAL CONTROLLER
NL1029015A1 (nl)	2005-11-15	Therapeutische verbindingen.
DE602006004866D1 (de)	2009-03-05	Katheter
DE602005026235D1 (de)	2011-03-24	Kapsel-endoskop
DK1733707T3 (da)	2008-11-10	Infusionskanylesystem
DE602006021176D1 (de)	2011-05-19	Endoskop
EP1908390A4 (en)	2009-12-16	Borescope
NO20070251A (no)	2007-03-12	Brønnbehandling
NO20070297A (no)	2007-03-12	Brønnbehandling
DE602004021940D1 (de)	2009-08-20	Endoskopsystem
DK1863899T3 (da)	2013-10-14	Hudbehandlingspræparater
DK2035369T3 (da)	2014-10-06	Terapeutiske
FR2898636B1 (fr)	2012-05-18	Structure de queue-d'aronde de soufflante.
DE602005017840D1 (de)	2010-01-07	Blutdruckmonitor
BRPI0808246A2 (pt)	2018-10-30	"fralda descartável".
EP1891880A4 (en)	2009-12-16	Borescope
DE602006016764D1 (de)	2010-10-21	Medizinisches Telemetriesystem
EP2052757A4 (en)	2009-12-02	MEDICAL CAPSULE
DE602006006131D1 (de)	2009-05-20	Endoskop
BRPI0716374A2 (pt)	2016-05-10	"dispositivos médicos"